Navigation Links
UCI Professor Zhibin Guan Joins NuGene Advisory Board
Date:3/30/2015

IRVINE, Calif., March 30, 2015 /PRNewswire/ -- NuGene International, Inc. ("NuGene") (OTCQB: NUGN), announced today that its subsidiary corporation, NuGene BioPharma, Inc. has added another internationally recognized researcher to its advisory board.

Dr. Guan is an internationally recognized researcher in bio-inspired materials and bio-materials fields. After finishing his college education at Peking University, China, Professor Guan received his Ph.D. degree from the University of North Carolina, Chapel Hill. Following a postdoctoral training at the California Institute of Technology (Caltech), he spent five years working at the Central Research and Development Laboratory of DuPont as a Senior Research Scientist.

He became a faculty member with the Chemistry, Biomedical Engineering, and Chemical Engineering and Materials Science departments of the University of California, Irvine in 2000 and was promoted to full professor in 2006.

Professor Guan is recognized for his contributions to macromolecular chemistry, bio-inspired materials design, and functional bio-materials for tissue engineering and gene delivery. He is the author of more than 80 publications in peer-reviewed journals including Science, Nature Materials, Nature Biotechnology, Nature Chemistry, etc.

Dr. Guan is the inventor of more than a dozen patents, and his work has been cited by others over 5000 times. He has received numerous awards including the Humboldt Bessel Research Award, the Camille Dreyfus Teacher-Scholar Award, the NSF CAREER Award, and the Beckman Young Investigator Award. In 2008, he was elected a Fellow of the American Association for the Advancement of Science.

"We continue to attract and recruit special talents to our advisory board," stated NuGene International's CEO Ali Kharazmi when announcing the addition. "His knowledge of functional bio-materials for tissue engineering and gene delivery is a perfect fit with our current board of advisors. As we seek to advance the stem cell enhanced cosmeceutical and pharmacological fields, Dr. Guan's expertise in these areas will be critical."

About NuGene International, Inc.

NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media.  The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments".  The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report.  NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue.  NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations.  The company has two patents pending covering 15 unique applications and inventions.  NuGene's goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 8-K filed with the Commission on January 6, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.

Investor/ Media Relations:
Chris Rosgen
Capital Market Relations
(949)481-9739

Logo - http://photos.prnewswire.com/prnh/20150303/179172LOGO

 


'/>"/>
SOURCE NuGene International, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Immunocore Appoints Professor Sir John Bell to its Board of Directors
2. Bioinformatics book by Waynesburg University professor published internationally
3. Professor Federico Rosei named to the Royal Society of Canada
4. Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain
5. UT Dallas professor receives Engineer of the Year award
6. John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva
7. American Physical Society names UT Arlington professor a fellow
8. Pioneer in Therapeutic Patient Education, Professor Jean-Philippe Assal, Wins 2013 IDF Europe Prize in Diabetes for Long-Standing Achievement
9. NJIT professor invents a flexible battery
10. Mainz University receives approval for an Alexander von Humboldt Professorship in Physics
11. Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2019)... ... January 22, 2019 , ... Outsourcing trials ... own set of assumptions, and RFP creation and management generally requires manual effort. ... comparing apples to oranges. These challenges can ultimately lead to study start delays ...
(Date:1/20/2019)... ... January 16, 2019 , ... On January 15 of this ... article by Asymmetrex director James L. Sherley, M.D., Ph.D. The PGCB ... like the PGCB and CellTrials.org. Now in its 21st year of operation, the ...
(Date:1/20/2019)... ... January 17, 2019 , ... Today, Advanced Solutions, Inc., a ... specialized automation technology, titled Automate 3D. Automate 3D, produced by Advanced Solutions, allows ... to deliver to end-users, customers, and ERP systems. , Automate 3D ...
(Date:1/15/2019)... ... ... Congress designating January as Cervical Health Awareness Month , myLAB Box , ... the risk of Cervical Cancer. , Cervical cancer is a slow-growing cancer that ... STD and an STI that almost half of all American adults have. While there ...
Breaking Biology Technology:
(Date:1/21/2019)... ... January 20, 2019 , ... Energetiq Technology, a world leader in ... at the SPIE BIOS and SPIE Photonics West events taking place in San Francisco ... booth #8526 at Bios and in booth #941 at Photonics West. There will be ...
(Date:1/20/2019)... SAN DIEGO (PRWEB) , ... January 16, 2019 , ... ... building and cooking events company. Not only has the company already hosted several ... to host Fortune 500 companies, Amazon and Janssen Pharmaceuticals, later this month. , ...
(Date:1/14/2019)... ... 14, 2019 , ... CellMax Life , a diagnostics ... will present new findings at the ASCO Gastrointestinal Cancer Symposium in San Francisco ... from this study show CellMax Life’s blood test, based on its proprietary CMxTM ...
Breaking Biology News(10 mins):